Figure 4.
Primary HRQoL assessments at day 1 (D1) and month 12 (M12) after ide-cel treatment. Patients with evaluable assessments at day 1 (n = 114 for all groups), at month 12 (n = 54 for all groups). D, day; HRQoL, health-related quality of life; M, month; QLQ-C30, Quality of Life C30 Questionnaire; QLQ-MY20, QLQ-C30 supplementary 20-item multiple myeloma module; QoL, quality of life.

Primary HRQoL assessments at day 1 (D1) and month 12 (M12) after ide-cel treatment. Patients with evaluable assessments at day 1 (n = 114 for all groups), at month 12 (n = 54 for all groups). D, day; HRQoL, health-related quality of life; M, month; QLQ-C30, Quality of Life C30 Questionnaire; QLQ-MY20, QLQ-C30 supplementary 20-item multiple myeloma module; QoL, quality of life.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal